Before You Book a Medicine Retreat: Psilocybin, Ayahuasca, and Ketamine

Three medicines, briefly

Psilocybin, the compound in certain mushrooms and truffles, produces a four-to-six-hour experience of altered perception, emotion, and meaning. It has the strongest clinical evidence of the three and the clearest path to legal, supervised use.

Ayahuasca is a brew from the Amazon that combines DMT with a plant that contains MAO inhibitors, which is what lets the DMT work when swallowed. The experience runs longer and is more physically demanding, often including purging, and it sits inside a ceremonial, shamanic tradition rather than a clinic.

Ketamine is a legal anesthetic used off-label for depression, and it is the only one of the three available under medical supervision across the United States. It is dissociative rather than classically psychedelic, and its effects are fast but often need maintenance.

Others come up in the same conversations. Ibogaine is used for opioid addiction and carries serious cardiac risk. 5-MeO-DMT is short and overwhelmingly intense. San Pedro and peyote carry mescaline in a slower, gentler arc. They matter, but psilocybin, ayahuasca, and ketamine are where most people start.

What they share, and where they part ways

All three open a window. For a few hours the usual defenses soften and material that is normally hard to reach becomes available. That is why set and setting, who you are with and where you are, matter as much as the dose, and why none of this is recreation. The work is in meeting what surfaces and carrying it home.

They part ways on almost everything else. Psilocybin and ketamine are measured in milligrams and minutes; ayahuasca is measured in nights and tradition. Ketamine is legal and clinical; psilocybin is legal only in specific places; ayahuasca is legal mostly abroad. The evidence is deep for psilocybin, growing for ketamine, and thinner and more observational for ayahuasca. The risk profiles differ too, which is the part worth slowing down for.

What the research actually shows

Psilocybin is the front-runner. COMPASS Pathways has now hit its primary endpoint in two Phase 3 trials of its synthetic psilocybin for treatment-resistant depression, and the compound holds Breakthrough Therapy designation from the FDA. Oregon has run licensed psilocybin service centers since 2023, and Colorado began issuing licenses in 2025. It remains federally Schedule I everywhere else.

Ayahuasca has a smaller but real evidence base. A 2019 randomized, placebo-controlled trial led by Fernanda Palhano-Fontes found a rapid antidepressant effect in treatment-resistant depression. Most of the rest is observational. DMT is federally Schedule I, with legal ceremonial use abroad and a narrow set of religious exemptions in the United States.

Ketamine is the most available. Esketamine, sold as Spravato, is FDA-approved for treatment-resistant depression, and racemic ketamine is widely used off-label. The catch is the delivery: the FDA warned in 2023 about compounded and at-home ketamine, and the risks of unsupervised use are well documented. The version worth considering is supervised and in-clinic.

Who these are not for

Screening is not a formality. A personal or family history of psychosis or bipolar disorder is a genuine contraindication, as are several heart conditions. The most dangerous interaction is ayahuasca with SSRIs, SNRIs, or other serotonergic medications, because of the MAO inhibitors in the brew. Never stop or combine medications on your own to qualify for a retreat. Work with a prescriber, and only with a program that screens you thoroughly.

A reputable operator will sometimes tell you no. That is not lost revenue being mishandled; it is the single clearest sign that you are dealing with people who take the work seriously.

Choosing where to go

Once you know which medicine fits your situation and the law where you are, the operator matters enormously. The signals to weigh are real medical and psychological screening, named and credentialed facilitators, on-site emergency protocols, genuine preparation and integration, clear informed consent, and how long the place has actually been running. Longevity is a trust signal in a field where many operations come and go.

We keep a vetted, regularly checked shortlist in our guide to the best medicine retreats, from MycoMeditations in Jamaica, running since 2014, to medically licensed ayahuasca at Rythmia in Costa Rica, to supervised ketamine-assisted psychotherapy at clinics like the Psychedelic Science Institute. If your interest is broader wellness rather than psychedelics specifically, our guide to wellness retreats in the US is the better starting point.

The GuideThe Best Medicine Retreats, comparedSee all seven, side by side →

The retreat is the easy part

Here is the thing the brochures underplay. The experience itself is vivid and often profound, and it is also the easiest part to buy. The hard part, the part that decides whether anything lasts, is what happens in the ordinary weeks on either side. Preparation sets the intention. Integration turns insight into changed behavior. Without them, a powerful weekend tends to fade into a good story.

This is the same truth that runs through mental and emotional well-being generally: single-cause stories rarely hold. A life is shaped by many forces at once, the body and its sleep, the people in the room, the meaning the days carry. A medicine session can loosen a stuck pattern, but the pattern reforms unless the surrounding life changes with it.

That line sits at the center of how we think about soul and spirit, and it applies here too. The deepest work is rarely done alone in an altered state; it is held by relationships, practice, and a life arranged to support the change. Integration is not an add-on. It is where the value is realized or lost. A simple, repeatable practice is often the best place to begin.